-
Featured Authors
Patently BIOtech
Archive
- May 2013 (1)
- April 2013 (5)
- March 2013 (2)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- October 2012 (3)
- September 2012 (3)
- August 2012 (5)
- July 2012 (4)
- June 2012 (7)
- May 2012 (5)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
Biotechnology Patenting in Europe Event
BIO hosted a Biotechnology Patenting in Europe event last week here at BIO’s offices where attorneys from Carpmaels and Ransford addressed various issues of interest to U.S. biotechnology companies. Huw Halleybone discussed the relative challenges of patent harmonization in Europe quoting some reports that indicate that the cost of a European patent is 10 times the amount of the United States. Most of this cost is mainly due to language translation requirements and renewal fees. Read More >
Patent Reform Inches Closer to Becoming Law
Yesterday, Senate Majority Leader Harry Reid (D-NV) filed for cloture for The Leahy-Smith America Invents Act, H.R. 1249, bringing it one step closer to becoming law. When the Senate reconvenes in September, patent reform will be at the top of the agenda. In his comments on the Congressional compromise on the debt ceiling, President Obama included patent reform in the list of action needed to stimulate the economy and create jobs: “Through patent reform, we Read More >
Bayh Dole Act a Failure? Part II: The Comments
By Guest Joseph Allen Yesterday we posted the reply of Robin Rasor, President of the Assn of University Technology Managers, to a Washington Post opinion piece by Vivek Wadhwa asserting that the university/industry technology transfer model established under the Bayh-Dole Act had failed and should be replaced. The article set off a series of comments, the most interesting of which occurred when Mr Wadhwa challenged Rasor to document the statistics she used asserting the Bayh-Dole Read More >
Bayh Dole Act a failure?
By Guest Writer Joseph Allen One hotly debated topic in Washington of real importance to the biotechnology community is how well the annual multi-billion dollar federal investment in R&D is being translated into new products, jobs and companies needed to improve the lives of US taxpayers and help pull the US economy out of its current doldrums. An interesting insight on the debate is captured in a Washington Post article “Innovation’s golden opportunity” that ran Read More >
